Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard

Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard

Shots:

  • Exact & Mayo has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, incidence, and mortality rates. The Voyage study will provide additional, real-world evidence demonstrating the clinical impact of Cologuard & position it as SoC in colorectal cancer screening
  • The Voyage study is a prospective, observational study, enrolling 150,000+ people with a valid Cologuard order and follow them for at least seven years to evaluate clinical outcomes
  • Cologuard is the only FDA-approved, at-home colorectal cancer screening test having the potential to improve screening rates in patients with colorectal cancer and has received FDA’s approval in Aug’14

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology